HOLLISTON, Mass. -- (BUSINESS WIRE) -- Harvard Apparatus Regenerative Technology, Inc. (NASDAQ:HART), a clinical stage biotechnology company developing regenerated organs for transplant, initially focused on the trachea, will announce results of its first quarter ended March 31, 2014 before market trading hours on Thursday, May 8, 2014. A conference call to discuss the company’s first quarter results and the company’s operations is scheduled for that same day at 11:00 AM (Eastern Time). On that call, management may respond to questions from the audience on any of a number of topics related to the business, including operations, plans and outlook.
Participating in the call will be David Green, President and Chief Executive Officer, and Tom McNaughton, Chief Financial Officer, of HART.
Investors can access the live conference call by dialing the following phone numbers: toll-free 888-395-3227, or toll/international 719-325-2469, and referencing the pass code “5263257”.
If you are unable to listen to the live conference call, a replay will be available from approximately 2:00 PM (Eastern Time) on May 8, 2014 through May 15, 2014 and will be accessible by dialing toll free 888-203-1112, or toll/international 719-457-0820, and referencing the pass code “5263257”.
About Harvard Apparatus Regenerative Technology
Harvard Apparatus Regenerative Technology makes regenerated organs for transplant. Our first product, the HART-Trachea, is intended to replace or repair a trachea that has been severely damaged by either physical trauma or trachea cancer. Our technology has been used in eight human trachea transplants to date approved under compassionate use exemptions, but none of our products are yet approved by a government regulatory authority for marketing. On November 1, 2013, HART was spun-off from Harvard Bioscience. The trademark “Harvard Apparatus” is used under a sublicense agreement with Harvard Bioscience, who has licensed the right to use such trademark from Harvard University.